AstraZeneca Pharma’s stock experienced a remarkable 12% surge after the approval of Durvalumab (Imfinzi) for treating non-small cell lung cancer in India. This key regulatory milestone opens new avenues for the company in the oncology market, reflecting growing investor confidence in its innovative therapies. Explore the implications of this approval and what it means for AstraZeneca’s future.